IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Serum Adiponectin in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases
The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2011 by Xijing Hospital.
Recruitment status was: Recruiting
Recruitment status was: Recruiting
Sponsor:
Xijing Hospital
Information provided by (Responsible Party):
Xijing Hospital
ClinicalTrials.gov Identifier:
NCT01372800
First received: June 10, 2011
Last updated: November 19, 2013
Last verified: November 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Adiponectin (Ad) is an abundant protein in human body, and reports have shown that it act as a novel risk factor for brain and heart ischemia injury. This 5 years follow-up study will focus on serum adiponectin concentration, activity and isoforms in Chinese population and its correlation to these diseases.
| Condition |
|---|
| Myocardial Infarction Cerebral Infarction |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Serum Adiponectin Concentration, Activity and Isoforms in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases |
Further study details as provided by Xijing Hospital:
Primary Outcome Measures:
- Number of Participants with major adverse events [ Time Frame: 5 years ]Major adverse events included but were not limited to death during the study caused by cardiovascular events or cerebrovascular events.
Secondary Outcome Measures:
- blood routine, glucose and lipid profile; ECG; [ Time Frame: 5 years ]the tests mentioned above will be taken once per year
- serum adiponectin concentration, activity and isoforms [ Time Frame: 5 years ]serum adiponectin concentration, activity and isoforms will be monitored once per year.
Biospecimen Retention: None Retained
blood
| Estimated Enrollment: | 30000 |
| Study Start Date: | May 2011 |
| Estimated Primary Completion Date: | October 2016 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
| volunteer |
Detailed Description:
Adiponectin (Ad) is an abundant protein hormone regulatory of numerous metabolic processes, anti-inflammatory, vascular protective, and anti-ischemic properties. Since its 1995 discovery, Ad has garnered considerable attention for its role in diabetic and cardiovascular pathology. Clinical observations have demonstrated the association of hypoadiponectinemia in patients with obesity, cardiovascular disease, and insulin resistance. There is growing evidence supporting Ad can act as a novel risk factor for cardiovascular and cerebrovascular injury. This 5 years follow-up study will focus on serum adiponectin concentration, activity and isoforms in Chinese population and its correlation to cardiovascular and cerebrovascular diseases.
Eligibility| Ages Eligible for Study: | 18 Years to 85 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Study Population
volunteer
Criteria
Inclusion Criteria:
- available for 5 years of follow-up study
Exclusion Criteria:
- Death caused other than cardiovascular and cerebralvascular diseases till the study ends
- Floating Population
- Pregnancy, lactation, or child bearing women
- Tumor
- Active hepatic disease or hepatic dysfunction, or AST/ALT > 1.5UNL
- Severe renal dysfunction(Scr > 3 mg/dl or 264μmol/L)
- Patients with any condition which, in the investigator's judgment, might increase the risk to the subject for any adverse event or abnormal laboratory finding
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01372800
Please refer to this study by its ClinicalTrials.gov identifier: NCT01372800
Contacts
| Contact: Ling Tao, M.D Ph.D | +86-15002955798 | lingtao2006@gmail.com |
Locations
| China, Shaanxi | |
| Xijing Hospital | Recruiting |
| Xi'an, Shaanxi, China, 710032 | |
| Contact: Ling Tao, M.D Ph.D +86-15002955798 lingtao2006@gmail.com | |
| Principal Investigator: Ling Tao, M.D Ph.D | |
Sponsors and Collaborators
Xijing Hospital
More Information
| Responsible Party: | Xijing Hospital |
| ClinicalTrials.gov Identifier: | NCT01372800 History of Changes |
| Other Study ID Numbers: |
xj050503 |
| Study First Received: | June 10, 2011 |
| Last Updated: | November 19, 2013 |
Keywords provided by Xijing Hospital:
|
adiponectin cardiovascular diseases cerebrovascular diseases |
Additional relevant MeSH terms:
|
Infarction Myocardial Infarction Cerebral Infarction Cerebrovascular Disorders Ischemia Pathologic Processes Necrosis Myocardial Ischemia Heart Diseases |
Cardiovascular Diseases Vascular Diseases Brain Infarction Brain Ischemia Brain Diseases Central Nervous System Diseases Nervous System Diseases Stroke |
ClinicalTrials.gov processed this record on June 28, 2017